BRAVOS for dcSSc (Scleroderma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if the study drug, brentuximab vedotin, is safe and will reduce symptoms in people who have dcSSc.
Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Who Can Participate in the Study?
Adults age 18-70 who have been diagnosed with dcSSC for 5 years or less
What is Involved?
If you choose to join this study, you will:
- Be randomized (like flipping a coin) to get the study drug, brentuximab vedotin, or a placebo (an inactive pill)
- Have physical exams, EKGs, and echocardiograms (an ultrasound test of your heart)
- Have a tuberculosis skin test, breathing (pulmonary function) test, and routine blood tests
- Have two skin biopsies